A Study of Apatinib in Combination With Raltitrexed Treatment in Patients With Advanced Colorectal Cancer

Sponsor
Chinese PLA General Hospital
Study ID
NCT03344614
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

30 patients with advanced colorectal cancer will be enrolled to observe the efficacy and safety of raltitrexed combined with apatinib as a third-line treatment.

Key Dates

Start date
Jul 1, 2017
Status verified
Oct 2017
Primary completion
Jan 1, 2019
Completion
Jul 1, 2019

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: raltitrexed combined with apatinib
    therapeutic regimen : raltitrexed, 3 mg/㎡, ivgtt, d1, apatinib 500 mg, QD po, d1-21, Every 3 weeks for 1 cycles.

Primary Outcome Measure

PFS [ Time Frame: 6 months ]

Central Contacts

Related Studies